Q-omics provides the consensus-scored MFSD12 profile across patient tissues and cancer cell-line models. MFSD12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MFSD12 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, MFSD12 RNA expression shows 18,772 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where MFSD12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD12 survival associations across molecular data types. MFSD12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD12 RNA expression–survival associations across cancer types. High MFSD12 expression shows unfavorable associations in ACC, MESO, LUAD, LGG and SKCM, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MFSD12 RNA expression.
This table summarizes MFSD12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MFSD12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD12 shows higher tumor expression in COAD, HNSC, STAD, LIHC, LUAD and BLCA. The COAD box plot shows higher MFSD12 RNA expression in tumor versus normal tissue (log2 FC = +2.054, t-test p < 0.001).
This table shows molecular features associated with MFSD12 in patient tissues and cancer cell lines. In patient samples, MFSD12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
